Astellas farms out third molecule to Drais
This article was originally published in Scrip
Executive Summary
Astellas is licensing out its third molecule in a year to a company affiliated with the US venture Drais Pharmaceuticals, in the continuing pursuit of a "multi-track" R&D strategy that allows the continued development of promising projects while sharing costs.